BN Business News
会社を追加 →
この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。

ビジネス · 2011/8/81 分で読めます

Prospective Grant of Exclusive License: Use of PKM2 Activators for the Treatment of Cancer

ローカル自動翻訳 · 情報源の原言語

概要

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Provisional Patent Application No. 61/104,091, entitled "Activators of Human Pyruvate Kinase," filed October 9, 2008, now abandoned [HHS Ref. No. E-326-2008/0-US-01]; PCT/US2009/60237 Application entitled "Small Molecule Activators of Pyruvate Kinase," filed October 9, 2009, now abandoned [HHS Ref. No. E-326-2008/0-PCT-02]; EP Application No. 09740795.1, entitled "Small Molecule Activators of Pyruvate Kinase," filed October 9, 2009 [HHS Ref. No. E-326-2008/0-EP-05]; U.S. Non- Provisional Application No. 13/123,297, entitled "Small Molecule Activators of Pyruvate Kinase," filed April 8, 2011 [HHS Ref. No. E-326-2008/0-US-07]; Australian National Application No. 2009303335, entitled "Small Molecule Activators of Pyruvate Kinase," filed October 9, 2010 [HHS Ref. No. E-326-2008/0-AU-03]; Canadian National Application, entitled "Small Molecule Activators of Pyruvate Kinase," filing date pending [HHS Ref. No. E-326-2008/0-CA-04

情報源の原言語: Federal Register — Health and Human Services原文の発表を開く →

関連インサイト

ビジネスインサイト →